<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758716</url>
  </required_header>
  <id_info>
    <org_study_id>FB825CLIIS-01-AD</org_study_id>
    <nct_id>NCT03758716</nct_id>
  </id_info>
  <brief_title>An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis</brief_title>
  <official_title>An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fountain Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fountain Biopharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with&#xD;
      Atopic Dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-labeled exploratory study to evaluate safety and efficacy of FB825 in adults&#xD;
      with atopic dermatitis (AD). The study will be conduct at one medical center in Taiwan.&#xD;
&#xD;
      Approximately 12 subjects with atopic dermatitis (AD), who meet the criteria for study entry,&#xD;
      will be enrolled to the one-arm-study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Actual">September 19, 2019</completion_date>
  <primary_completion_date type="Actual">January 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% Change From Baseline in Total IgE</measure>
    <time_frame>Day 169</time_frame>
    <description>Detect total IgE in serum by ImmunoCAP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>% Change From Baseline in Allergen-specific IgE</measure>
    <time_frame>Day 169</time_frame>
    <description>Detect specific IgE in serum by ImmunoCAP. (ex. Ragweed)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total IgE</measure>
    <time_frame>Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)</time_frame>
    <description>Detect total IgE in serum by ImmunoCAP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Change From Baseline in Allergen-specific IgE</measure>
    <time_frame>Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)</time_frame>
    <description>Detect specific IgE in serum by ImmunoCAP. (Dog dander)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Irritability Visual Analogue Scale (VAS)</measure>
    <time_frame>Days 85</time_frame>
    <description>VAS measurement follow the normal by Principal Investigator, range from 0-20. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Day 85</time_frame>
    <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD)</measure>
    <time_frame>Days 169</time_frame>
    <description>SCORAD measurement follow the normal by Principal Investigator, range from 0-103. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Investigator Global Assessment (IGA) for Atopic Dermatitis</measure>
    <time_frame>Days 169</time_frame>
    <description>IGA measurement follow the normal by Principal Investigator, range from 0-4. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Body Surface Area (BSA) Involved in Atopic Dermatitis</measure>
    <time_frame>Days 169</time_frame>
    <description>BSA measurement follow the normal by Principal Investigator, range from 0-100. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Will be Assessed by Monitoring and Recording of Adverse Events (AEs) and Serious Adverse Event (SAEs)</measure>
    <time_frame>through study completion, an average of 1 year.</time_frame>
    <description>Safety will be assessed by monitoring and recording of adverse events (AEs) and serious adverse event (SAEs); physical examination findings and vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature), clinical laboratory test results (hematology, coagulation, serum chemistry [including liver function tests, blood glucose level], and urinalysis); 12-lead ECG results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Day 57</time_frame>
    <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Day 113</time_frame>
    <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Day 141</time_frame>
    <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Changes From Baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Day 169</time_frame>
    <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>FB825</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FB825, FB825-15D11, Anti-CemX</intervention_name>
    <description>Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
    <arm_group_label>FB825</arm_group_label>
    <other_name>FB825-15D11, Lot # 16-2056</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects between 20 and 65 years of age, inclusive.&#xD;
&#xD;
          2. The subject has a physician-confirmed diagnosis of chronic atopic dermatitis based on&#xD;
             3 years history of symptoms defined by the Eichenfield revised criteria of Hannifin&#xD;
             and Rajka and supported by positive allergen-specific IgE at the screening visit.&#xD;
&#xD;
          3. Eczema Area and Severity Index (EASI) score ≧14 at the screening and baseline visits.&#xD;
&#xD;
          4. Investigator's Global Assessment (IGA) score ≧ 3 (5-point scale) at the screening and&#xD;
             baseline visits.&#xD;
&#xD;
          5. ≧10 % body surface area (BSA) of AD involvement at the screening and baseline visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant or lactating.&#xD;
&#xD;
          2. The subject is on diet or with poor intake.&#xD;
&#xD;
          3. The subject has a history of heart arrhythmias (any clinically relevant).&#xD;
&#xD;
          4. The subject has a positive test result for hepatitis B surface antigen, hepatitis C&#xD;
             virus antibody, or human immunodeficiency virus types 1 and 2 antibodies at screening.&#xD;
&#xD;
          5. The subject has a history of alcohol or drug abuse that would impair or risk the&#xD;
             patients' full participation in the study, in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Yu Chu, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <results_first_submitted>January 8, 2021</results_first_submitted>
  <results_first_submitted_qc>February 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2021</results_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03758716/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FB825</title>
          <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FB825</title>
          <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.75" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total IgE</title>
          <description>Total IgE (immunoglobulin E)</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6611.53" spread="6693.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>EASI Scores</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.98" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% Change From Baseline in Total IgE</title>
        <description>Detect total IgE in serum by ImmunoCAP.</description>
        <time_frame>Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Change From Baseline in Total IgE</title>
          <description>Detect total IgE in serum by ImmunoCAP.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.57" spread="21.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>% Change From Baseline in Allergen-specific IgE</title>
        <description>Detect specific IgE in serum by ImmunoCAP. (ex. Ragweed)</description>
        <time_frame>Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Change From Baseline in Allergen-specific IgE</title>
          <description>Detect specific IgE in serum by ImmunoCAP. (ex. Ragweed)</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.16" spread="23.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total IgE</title>
        <description>Detect total IgE in serum by ImmunoCAP.</description>
        <time_frame>Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total IgE</title>
          <description>Detect total IgE in serum by ImmunoCAP.</description>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="482.93" spread="1528.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137.70" spread="1634.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-298.07" spread="1874.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-862.73" spread="1934.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1956.86" spread="2880.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1581.65" spread="2253.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1419.49" spread="2901.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1968.97" spread="2668.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2350.48" spread="3023.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 169/ EOS (end of study)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2817.01" spread="3708.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Change From Baseline in Allergen-specific IgE</title>
        <description>Detect specific IgE in serum by ImmunoCAP. (Dog dander)</description>
        <time_frame>Day 8, 15, 29, 57, and day 85 (And Day 92, 99, 113, 141 and 169 if received the second dose of FB825)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Change From Baseline in Allergen-specific IgE</title>
          <description>Detect specific IgE in serum by ImmunoCAP. (Dog dander)</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dose 1 Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="12.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.81" spread="17.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.83" spread="21.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 1 Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.38" spread="20.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.44" spread="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.22" spread="17.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.30" spread="17.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 113</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.02" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 141</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.07" spread="16.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dose 2 Day 169/ EOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.94" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Irritability Visual Analogue Scale (VAS)</title>
        <description>VAS measurement follow the normal by Principal Investigator, range from 0-20. The lower the scores the better situation of the patient.</description>
        <time_frame>Days 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Irritability Visual Analogue Scale (VAS)</title>
          <description>VAS measurement follow the normal by Principal Investigator, range from 0-20. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.57" spread="30.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
        <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
        <time_frame>Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.33" spread="41.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD)</title>
        <description>SCORAD measurement follow the normal by Principal Investigator, range from 0-103. The lower the scores the better situation of the patient.</description>
        <time_frame>Days 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Severity Scoring of Atopic Dermatitis Index (SCORAD)</title>
          <description>SCORAD measurement follow the normal by Principal Investigator, range from 0-103. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.19" spread="15.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Investigator Global Assessment (IGA) for Atopic Dermatitis</title>
        <description>IGA measurement follow the normal by Principal Investigator, range from 0-4. The lower the scores the better situation of the patient.</description>
        <time_frame>Days 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Investigator Global Assessment (IGA) for Atopic Dermatitis</title>
          <description>IGA measurement follow the normal by Principal Investigator, range from 0-4. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.58" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Body Surface Area (BSA) Involved in Atopic Dermatitis</title>
        <description>BSA measurement follow the normal by Principal Investigator, range from 0-100. The lower the scores the better situation of the patient.</description>
        <time_frame>Days 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Body Surface Area (BSA) Involved in Atopic Dermatitis</title>
          <description>BSA measurement follow the normal by Principal Investigator, range from 0-100. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.04" spread="26.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Will be Assessed by Monitoring and Recording of Adverse Events (AEs) and Serious Adverse Event (SAEs)</title>
        <description>Safety will be assessed by monitoring and recording of adverse events (AEs) and serious adverse event (SAEs); physical examination findings and vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and body temperature), clinical laboratory test results (hematology, coagulation, serum chemistry [including liver function tests, blood glucose level], and urinalysis); 12-lead ECG results.</description>
        <time_frame>through study completion, an average of 1 year.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
        <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
        <time_frame>Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.09" spread="29.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
        <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
        <time_frame>Day 113</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70.00" spread="34.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
        <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
        <time_frame>Day 141</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.12" spread="25.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
        <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
        <time_frame>Day 169</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FB825</title>
            <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
          </group>
        </group_list>
        <measure>
          <title>% Changes From Baseline in Eczema Area and Severity Index (EASI)</title>
          <description>EASI measurement follow the normal by Principal Investigator. range from 0-72. The lower the scores the better situation of the patient.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-72.14" spread="20.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>169 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FB825</title>
          <description>Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.&#xD;
FB825, FB825-15D11, Anti-CemX: Pharmaceutical form: 20mg/ml solution Route of administration: IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>NienYi Chen PhD</name_or_title>
      <organization>Oneness Biotech Co., Ltd.</organization>
      <phone>+886 2 2655 8687 ext 613</phone>
      <email>nienyichen@onenessbio.com.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

